Johnson & Johnson to settle talc baby powder investigation, will reportedly pay $700 million

Johnson & Johnson to settle talc baby powder investigation, will reportedly pay 0 million


In this photo illustration, a container of Johnson and Johnson baby powder is displayed on April 05, 2023 in San Anselmo, California. 

Justin Sullivan | Getty Images

Johnson & Johnson has reached a tentative settlement to resolve an investigation by more than 40 states into claims that the company misled patients about the safety of its talc baby powder and other talc-based products, the company said in a statement to CNBC on Tuesday. 

Notably, the settlement does not resolve the tens of thousands of consumer lawsuits, some of which are slated to go to trial this year, alleging that those talc-based products caused cancer.

Those cases have for decades caused financial and public relations trouble for J&J, which contends that its now-discontinued talc products are safe for consumers.

J&J said in an October securities filing that 42 states and Washington, D.C., had launched a joint investigation into its marketing of talc-based products. The company will pay $700 million to settle the probe, its CFO Joseph Wolk told the Wall Street Journal Tuesday.

Last year, J&J only set aside about $400 million to resolve U.S. state consumer protection claims.

Erik Haas, J&J’s worldwide vice president of litigation, confirmed the settlement in a statement to CNBC. He did not provide the payment amount or further details on the deal.

“Consistent with the plan we outlined last year, the company continues to pursue several paths to achieve a comprehensive and final resolution of the talc litigation,” Haas told CNBC. “As was leaked last week, that progress includes an agreement in principle that the Company reached with a consortium of 43 State Attorneys Generals to resolve their talc claims.”

Bloomberg first reported about the settlement earlier this month, citing sources familiar with the matter. 

J&J, which reported fourth-quarter results on Tuesday, has twice tried to resolve the consumer talc cases by offloading those liabilities into a subsidiary, LTL Management, and having that unit file for Chapter 11 bankruptcy protection. 

A New Jersey bankruptcy judge in July rejected the second bankruptcy attempt, stating that LTL Management wasn’t in sufficient financial distress. A U.S. appeals court in April dismissed the first bankruptcy attempt for the same reason. 

As part of the latest failed bankruptcy attempt, J&J proposed to pay $8.9 billion to talc claimants.

J&J said late last year that it is considering a third bankruptcy attempt as it tries to push forward with that proposal.

J&J ended sales of its talc-based baby powder globally last year.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More